News
Otsuka grows in neuroplastogens with $1.225bn Transcend buy
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
News
Lilly puts up to $2.75bn into Insilico alliance
Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
R&D
Ending trial-and-error: How psychedelics and precision medic...
The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
News
Where others missed, AZ's IL-33 drug hits the mark in COPD
AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.
News
Novartis snaps up food allergy firm Excellergy for $2bn
Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
